Pharma doesn’t always need a brand-new drug to extend its profits.
Sometimes it just needs a new version—and a legal pathway that lets it re-enter the patent landscape without starting from scratch.
That’s the core idea behind the “reformulation playbo…

Drug spend isn’t a mystery problem—it’s a timing problem.
If you’re a payer, pharmacy benefit manager, hospital system, or procurement leader, you already know the pain: drug costs rise, formularies get pressured, and “we’ll negotiate next quarter” b…

The Drug Patent Cliff Is Here—And Procurement Teams Are About to Pay for It
If you manage sourcing, contracts, or spend analytics, you already know the uncomfortable truth: drug pricing doesn’t just “happen.” It arrives—often on a predictable timetable…

The Hidden IP Trap in Clinical Research: How Unvetted Software and AI Imperil Sponsor Patents
Clinical development is already a high-wire act—regulatory timelines, trial complexity, data integrity, and patient safety. But there’s a quieter risk that’s …

The “Hard 20-Year Limit” in New Zealand Isn’t Just a Legal Detail—it’s the Clock That Decides Who Wins.
In drug development, timelines are everything. But in New Zealand, one particular timeline—an unusually rigid “hard 20-year limit”—quietly shapes al…

Most people in pharma think they understand “patent dates.” They don’t.
If you work in drug development, regulatory strategy, or commercial planning, you’ve probably seen it: a spreadsheet with a clean-looking “patent expiry” date—followed by a scram…

Pharma companies are sitting on a paradox: they spend billions to invent life-saving therapies—and then leave value on the table when it comes to protecting that value across borders.
That’s the core tension behind the “patent box” conversation. In pla…

180 Days: The Generic Launch Window That Can Make (or Break) a Fortune
In generic drugs, timing isn’t just strategy—it’s destiny.
There’s a reason the industry talks about “the 180-day exclusivity” like it’s a high-stakes countdown clock. For some comp…

Europe’s “Divisional Patent Trap”: How Big Pharma Can Delay Generics Without Losing in Court
If you’ve ever wondered how a company can keep generics off the market for years—without ever “losing” a lawsuit—Europe’s divisional patent system offers a pla…

Biopharma is in a talent arms race—and most companies are playing defense.
While everyone focuses on the next clinical readout, the next IND, the next partnership, the real competitive edge is often hiding in plain sight: who you hire before the scienc…